A WHIM satisfactorily addressed
- PMID: 24723677
- DOI: 10.1182/blood-2014-02-557579
A WHIM satisfactorily addressed
Abstract
In this issue of Blood, McDermott et al present the intriguing, clinically relevant, and perhaps unexpected findings for the efficacy and safety of long-term administration of low-dose plerixafor treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.
Trial registration: ClinicalTrials.gov NCT00967785.
Comment on
-
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12. Blood. 2014. PMID: 24523241 Free PMC article. Clinical Trial.
Similar articles
-
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12. Blood. 2014. PMID: 24523241 Free PMC article. Clinical Trial.
-
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.Blood. 2011 Nov 3;118(18):4957-62. doi: 10.1182/blood-2011-07-368084. Epub 2011 Sep 2. Blood. 2011. PMID: 21890643 Free PMC article. Clinical Trial.
-
Plerixafor for the Treatment of WHIM Syndrome.N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575. N Engl J Med. 2019. PMID: 30625055 Free PMC article.
-
Genetics on a WHIM.Br J Haematol. 2014 Jan;164(1):15-23. doi: 10.1111/bjh.12574. Epub 2013 Sep 20. Br J Haematol. 2014. PMID: 24111611 Free PMC article. Review.
-
Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.Curr Mol Med. 2011 Jun;11(4):317-25. doi: 10.2174/156652411795677963. Curr Mol Med. 2011. PMID: 21506920 Review.
Publication types
MeSH terms
Substances
Supplementary concepts
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical